 
    The world is on the threshold of a great new industrial revolution, a 1 scientific-industrial revolution. Recombinant DNA technology and hybridoma technology ("monoclonal antibodies") have already pro vided unique investment opportunities for venture capitalists. Hence published reports of biomedical research are no longer restricted to scientific journals, but now appear regularly not only in weekly news 2 magazines like Time and U. S. News & World Report,3 but also in the financial sections of The New York Times,4 The Wall Street Journal,S 6 8 Business Week, Fortune,7 and The Economist, as well as in such stock 9 market advisory publications as New Issues and Inc. (The Magazine for Growing Companies). 10 These publications now appear to be as impor tant to biomedical scientists in keeping abreast of new scientific devel opments in biotechnology as is Current Contents. (The costs of health cost provision and of fundamental biomedical research are now also being followed by such media. ) Conversely, Wall Street financial bro kers increasingly no longer confine their reading to economic journals but are also perusing Nature,ll Science,12 and Science N 13 for infor ews mation on both fiscal and scientific advances in these areas. It is obvious that the information explosion in biotechnology is crossing traditional boundaries (e. g. , ref. 14). This volume is the second of several that are intended to inform both the biomedical community and interested intelligent laymen of the political and economic implications of biomedical research.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
The world is on the threshold of a great new industrial revolution, a 1 scientific-industrial revolution. Recombinant DNA technology and hybridoma technology ("monoclonal antibodies") have already pro vided unique investment opportunities for venture capitalists. Hence published reports of biomedical research are no longer restricted to scientific journals, but now appear regularly not only in weekly news 2 magazines like Time and U. S. News & World Report,3 but also in the financial sections of The New York Times,4 The Wall Street Journal,S 6 8 Business Week, Fortune,7 and The Economist, as well as in such stock 9 market advisory publications as New Issues and Inc. (The Magazine for Growing Companies). 10 These publications now appear to be as impor tant to biomedical scientists in keeping abreast of new scientific devel opments in biotechnology as is Current Contents. (The costs of health cost provision and of fundamental biomedical research are now also being followed by such media. ) Conversely, Wall Street financial bro kers increasingly no longer confine their reading to economic journals but are also perusing Nature,ll Science,12 and Science N 13 for infor ews mation on both fiscal and scientific advances in these areas. It is obvious that the information explosion in biotechnology is crossing traditional boundaries (e. g. , ref. 14). This volume is the second of several that are intended to inform both the biomedical community and interested intelligent laymen of the political and economic implications of biomedical research.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Lucky's Textbooks, Dallas, TX, USA
Zustand: New. Bestandsnummer des Verkäufers ABLIING23Mar2716030068775
Anzahl: Mehr als 20 verfügbar
Anbieter: BargainBookStores, Grand Rapids, MI, USA
Paperback or Softback. Zustand: New. Biomedical Institutions, Biomedical Funding, and Public Policy. Book. Bestandsnummer des Verkäufers BBS-9781468444506
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In. Bestandsnummer des Verkäufers ria9781468444506_new
Anzahl: Mehr als 20 verfügbar
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The world is on the threshold of a great new industrial revolution, a 1 scientific-industrial revolution. Recombinant DNA technology and hybridoma technology ('monoclonal antibodies') have already pro vided unique investment opportunities for venture capitalists. Hence published reports of biomedical research are no longer restricted to scientific journals, but now appear regularly not only in weekly news 2 magazines like Time and U. S. News & World Report,3 but also in the financial sections of The New York Times,4 The Wall Street Journal,S 6 8 Business Week, Fortune,7 and The Economist, as well as in such stock 9 market advisory publications as New Issues and Inc. (The Magazine for Growing Companies). 10 These publications now appear to be as impor tant to biomedical scientists in keeping abreast of new scientific devel opments in biotechnology as is Current Contents. (The costs of health cost provision and of fundamental biomedical research are now also being followed by such media. ) Conversely, Wall Street financial bro kers increasingly no longer confine their reading to economic journals but are also perusing Nature,ll Science,12 and Science N 13 for infor ews mation on both fiscal and scientific advances in these areas. It is obvious that the information explosion in biotechnology is crossing traditional boundaries (e. g. , ref. 14). This volume is the second of several that are intended to inform both the biomedical community and interested intelligent laymen of the political and economic implications of biomedical research. 240 pp. Englisch. Bestandsnummer des Verkäufers 9781468444506
Anzahl: 2 verfügbar
Anbieter: Books Puddle, New York, NY, USA
Zustand: New. pp. 240. Bestandsnummer des Verkäufers 2698253288
Anbieter: THE SAINT BOOKSTORE, Southport, Vereinigtes Königreich
Paperback / softback. Zustand: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days 370. Bestandsnummer des Verkäufers C9781468444506
Anzahl: Mehr als 20 verfügbar
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. Print on Demand pp. 240 49:B&W 6.14 x 9.21 in or 234 x 156 mm (Royal 8vo) Perfect Bound on White w/Gloss Lam. Bestandsnummer des Verkäufers 95192631
Anzahl: 4 verfügbar
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. PRINT ON DEMAND pp. 240. Bestandsnummer des Verkäufers 1898253282
Anzahl: 4 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. Bestandsnummer des Verkäufers 4203877
Anzahl: Mehr als 20 verfügbar
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The world is on the threshold of a great new industrial revolution, a 1 scientific-industrial revolution. Recombinant DNA technology and hybridoma technology ('monoclonal antibodies') have already pro vided unique investment opportunities for venture capitalists. Hence published reports of biomedical research are no longer restricted to scientific journals, but now appear regularly not only in weekly news 2 magazines like Time and U. S. News & World Report,3 but also in the financial sections of The New York Times,4 The Wall Street Journal,S 6 8 Business Week, Fortune,7 and The Economist, as well as in such stock 9 market advisory publications as New Issues and Inc. (The Magazine for Growing Companies). 10 These publications now appear to be as impor tant to biomedical scientists in keeping abreast of new scientific devel opments in biotechnology as is Current Contents. (The costs of health cost provision and of fundamental biomedical research are now also being followed by such media. ) Conversely, Wall Street financial bro kers increasingly no longer confine their reading to economic journals but are also perusing Nature,ll Science,12 and Science N 13 for infor ews mation on both fiscal and scientific advances in these areas. It is obvious that the information explosion in biotechnology is crossing traditional boundaries (e. g. , ref. 14). This volume is the second of several that are intended to inform both the biomedical community and interested intelligent laymen of the political and economic implications of biomedical research.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 240 pp. Englisch. Bestandsnummer des Verkäufers 9781468444506
Anzahl: 1 verfügbar